-

AlgoTherapeutix appoints Prof Jens Ellrich Chief Medical Officer

PARIS--(BUSINESS WIRE)--AlgoTherapeutix (AlgoTx) is a European Biotech developing ATX01, a non-opioid topical treatment for Peripheral Neuropathic Pain.

Stéphane Thiroloix, CEO, comments : “With ATX01 entering Phase II in Chemotherapy-Induced Peripheral Neuropathy and increasing its span of indications, Jens’s medical depth of expertise and biotech experience are a tremendous addition to the team’s profile”.

Jens Ellrich, MD, PhD, spent 18 years in basic and clinical pain research at University hospitals in Germany and Denmark with a track record of more than 85 publications in scientific journals with peer review. He was full professor at RWTH Aachen University and Aalborg University and received the European Award for Pain Research in 2005.

Since 2010, Jens has served as Chief Medical Officer for the international neuroscience start-ups Cerbomed, EBS Technologies, Precisis, Sapiens, and WISE.

Besides his executive roles in the healthcare industry, he serves as adjunct professor of neuroscience at Erlangen University and is a member of the Editorial Advisory Board of the European Journal of Pain. Jens brings a wealth of hands-on experience and expertise in pain research, clinical development, and medical affairs.

About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. Its lead program, ATX01, is Phase II ready in painful peripheral neuropathy.

AlgoTherapeutix SAS
49 rue des Nouvelles - 92150 Suresnes

Stéphane Thiroloix - stephane@algotx.com

Contacts

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567
contact@cliquet-consultant.com

Industry:

AlgoTherapeutix

Release Versions
EnglishSpanish (Summary)GermanFrenchItalianDutch (Summary)

Contacts

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567
contact@cliquet-consultant.com

More News From AlgoTherapeutix

AlgoTx Progresses ATX01 in Two Indications

SURESNES, France--(BUSINESS WIRE)--European biotech AlgoTx, a clinical stage innovator in complex pain, today announces that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for its Phase 2 first-in-class candidate ATX01 in the treatment of erythromelalgia. Meanwhile, the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN). Both programs have been...

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain

SURESNES, France--(BUSINESS WIRE)--European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secure...

AlgoTherapeutix Announces Initiation of Global Phase 2 Clinical Trial of ATX01 for the Relief of Pain in Chemotherapy-induced Peripheral Neuropathy in Adults

SURESNES, France--(BUSINESS WIRE)--AlgoTx, a biotechnology company dedicated to developing treatments for complex pain, announced today the initiation of its Phase 2 global clinical trial in Chemotherapy-Induced Peripheral Neuropathy in adult patients. The trial will evaluate the efficacy and safety of two concentrations of ATX01 (proprietary topical amitriptyline). ATX01 received Fast-Track designation from the US Food & Drug Administration last June for its development in CIPN. “We are ex...
Back to Newsroom